Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2017 (2017), Article ID 2912763, 9 pages
https://doi.org/10.1155/2017/2912763
Research Article

Circulatory Immune Cells in Cushing Syndrome: Bystanders or Active Contributors to Atherometabolic Injury? A Study of Adhesion and Activation of Cell Surface Markers

1Group of Endocrine Disorders, IDIBAPS, Barcelona, Spain
2Department of Endocrinology and Nutrition, Hospital Clinic Universitari, Barcelona, Spain
3Cytometry Department, IDIBAPS, Barcelona, Spain
4Centro de Investigación en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain
5University of Barcelona, Barcelona, Spain
6Biochemistry and Molecular Genetics Service, Hospital Clinic Universitari and IDIBAPS and CIBERehd, Barcelona, Spain
7Department of Neurosurgery, Hospital Clinic Universitari, Barcelona, Spain

Correspondence should be addressed to Felicia A. Hanzu; tac.cinilc@uznahf

Received 22 February 2017; Revised 18 June 2017; Accepted 16 July 2017; Published 20 September 2017

Academic Editor: Sabrina Corbetta

Copyright © 2017 Gloria Aranda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Ferraú and M. Korbonits, “Metabolic comorbidities in Cushing’s syndrome,” European Journal of Endocrinology, vol. 173, pp. M133–M157, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Malek, M. M. Ebadzadeh, R. Safabakhsh, A. Razavi, and J. Zaringhalam, “Dynamics of the HPA axis and inflammatory cytokines: insights from mathematical modeling,” Computers in Biology and Medicine, vol. 67, pp. 1–12, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Kronfol, M. Starkman, D. Schteingart, V. Singh, Q. Zhang, and E. Hill, “Immune regulation in Cushing’s syndrome: relationship to hypothalamic-pituitary-adrenal axis hormones,” Psyconeuroendocrinology, vol. 21, pp. 599–608, 1996. View at Google Scholar
  4. J. F. Evans and L. Ragolia, “Systemic and local ACTH produced during inflammatory states promotes osteochondrogenic mesenchymal cell differentiation contributing to the pathological progression of calcified atherosclerosis,” Medical Hypotheses, vol. 79, no. 6, pp. 823–826, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Masri-Iraqui, E. Robenshtok, G. Tzvetov, Y. Manistersky, and I. Shimon, “Elevated white blood cell counts in Cushing’s disease: association with hypercortisolism,” Pituitary, vol. 17, pp. 436–440, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Getz, “Thematic review series: the immune system and atherogenesis. Immune function in atherogenesis,” Journal of Lipid Research, vol. 46, pp. 1–10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Libby, P. Ridker, and G. Hansson, “Inflammation in atherosclerosis: from pathophysiology to practice,” Journal of the American College of Cardiology, vol. 54, pp. 2129–2138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Tupin, A. Nicoletti, R. Elharge et al., “CD1d-dependent activation of NKT cells aggravates atherosclerosis,” The Journal of Experimental Medicine, vol. 199, pp. 417–422, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Drechsler, Y. Doering, R. T. Megens, and O. Soehnlein, “Neutrophilic granulocytes-promiscuous accelerators of atherosclerosis,” Thrombosis and Haemostasis, vol. 106, pp. 839–848, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Weber and H. Noels, “Atherosclerosis: current pathogenesis and therapeutic option,” Nature Medicine, vol. 17, pp. 1410–1422, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Meng, J. Yang, M. Dong et al., “Regulatory T cells in cardiovascular diseases,” Nature Reviews Cardioliogy, vol. 13, pp. 167–179, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. An Endocrine Society Clinical Practice Guideline, “The diagnosis of Cushing’s syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 93, pp. 1526–1540, 2008. View at Google Scholar
  13. G. H. Heine, A. Ortiz, Z. A. Massy et al., “Monocyte subpopulations and cardiovascular risk in chronic kidney disease,” Nature Reviews Nephrology, vol. 8, pp. 362–369, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. K. S. Rogacev, C. Ulrich, L. Blömer et al., “Monocyte heterogeneity in obesity and subclinical atherosclerosis,” European Heart Journal, vol. 31, pp. 369–376, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Hristov and C. Weber, “Differential role of monocyte subsets in atherosclerosis,” Thrombosis and Haemostasis, vol. 106, pp. 757–762, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Mosig, K. Renner, S. Krause et al., “Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14+CD16+ monocytes in detoxification of oxidized LDL,” FASEB Journal, vol. 23, pp. 866–874, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Belge, F. Dayyani, A. Horelt et al., “The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF,” Journal of Immunology, vol. 168, pp. 3536–3542, 2002. View at Google Scholar
  18. B. Liu, A. Dhanda, S. Hirani et al., “CD14++CD16+ monocytes are enriched by glucocorticoid treatment and are functionally attenuated in driving effector T cell responses,” Journal of Immunology, vol. 194, no. 11, pp. 5150–5160, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. K. S. Rogacev, B. Cremers, A. M. Zawada et al., “CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography,” Journal of American College of Cardiology, vol. 60, pp. 1512–1520, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Poitou, E. Dalmas, M. Renovato et al., “CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis,” Arteriosclerosis Thrombosis and Vascular Biology, vol. 31, no. 10, pp. 2322–2330, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. M. A. de Matos, T. C. Duarte, O. Ottone Vde et al., “The effect of insulin resistance and exercise on the percentage of CD16+ monocyte subset in obese individuals,” Cell Biochemistry Function, vol. 34, no. 4, pp. 209–216, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Idzkowska, A. Eljaszewicz, P. Miklasz, W. J. Musial, A. M. Tycinska, and M. Moniuszko, “The role of different monocyte subsets in the pathogenesis of atherosclerosis and acute coronary syndromes,” Scandinavian Journal of Immunology, vol. 82, no. 3, pp. 163–173, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. F. A. Dela Balze, E. C. Reifenstein Jr., and F. Albright, “Differential blood counts in certain adrenal cortical disorders (Cushing’s syndrome, Addison’s disease and panhypopituitarism),” Journal of Clinical Endocrinology and Metabolism, vol. 6, pp. 312–319, 1946. View at Publisher · View at Google Scholar
  24. M. Madjid, I. Awan, J. T. Willerson, and S. W. Casscells, “Leukocyte count and coronary heart disease: implications for risk assessment,” Journal of the American College of Cardiology, vol. 44, pp. 1945–1956, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Masera, A. Staurenghi, M. Sartori, and A. Angeli, “Natural killer cell activity in the peripheral blood of patients with Cushing’s syndrome,” European Journal of Endocrinology, vol. 140, pp. 299–306, 1999. View at Google Scholar
  26. G. S. Getz and C. A. Reardon, “Natural killer T cells in atherosclerosis,” Nature Reviews Cardiology, vol. 14, pp. 304–314, 2017. View at Publisher · View at Google Scholar
  27. M. Nakagawa, T. Terashima, Y. D’yachkova, G. P. Bondy, J. C. Hogg, and S. F. van Eeden, “Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes,” Circulation, vol. 98, pp. 2307–2313, 1998. View at Google Scholar
  28. G. Cox, “Glucocorticoids treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes,” Journal of Immunology, vol. 154, pp. 4719–4725, 1995. View at Google Scholar
  29. G. Hirsch Dtsvetov, Y. Manisterski, N. Aviran-Barak, V. Nadler, S. Alboim, and V. Kopel, “Incidence of Cushing’s syndrome in patients with significant hypercortisoluria,” European Journal of Endocrinology, vol. 176, no. 1, pp. 41–48, 2017. View at Publisher · View at Google Scholar
  30. M. Y. Desai, D. Dalal, R. D. Santos, J. A. Carvalho, K. Nasir, and R. S. Blumenthal, “Association of body mass index, metabolic syndrome, and leukocyte count,” The American Journal of Cardiology, vol. 97, no. 6, pp. 835–838, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Keresztes, T. Horvath, I. Ocsovszki et al., “ACTH- and cortisol associated neutrophil modulation in coronary artery disease patients undergoing stent implantation,” PLoS One, vol. 8, article e71902, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Adamsson Eryd, J. G. Smith, O. Melander, B. Hedblad, and G. Engström, “Incidence of coronary events and case fatality rate in relation to blood lymphocyte and neutrophil counts,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, pp. 533–539, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Ziegler-Heibrock, P. Ancuta, S. Crowe et al., “Nomenclature of monocytes and dendritic cells in blood,” Blood, vol. 116, pp. e74–e80, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Dayyani, K. U. Belge, M. Frankenberger, M. Mack, T. Berki, and L. Ziegler-Heitbrock, “Mechanism of glucocorticoid-induced depletion of human CD14+CD16+ monocytes,” Journal of Leukocyte Biology, vol. 74, pp. 33–39, 2003. View at Google Scholar
  35. N. Kawanaka, M. Yamamura, T. Aita et al., “CD14+CD16+ blood monocytes and joint inflammation in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 46, pp. 2578–2586, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. I. Heimbeck, T. P. Hofer, C. Eder et al., “Standardized single-platform assay for human monocyte subpopulations: lower CD14+CD16++ monocytes in females,” Cytometry Part A, vol. 9, pp. 823–830, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Fingerle-Rowson, M. Angstwurm, R. Andreesen, and H. W. Ziegler-Heitbrock, “Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy,” Clinical and Experimental Immunology, vol. 112, pp. 501–506, 1998. View at Google Scholar
  38. J. E. Scherberich and W. A. Nockher, “CD14++ monocytes, CD14+/CD16+ subset and soluble CD14 as biological markers of inflammatory systemic diseases and monitoring immunosuppressive therapy,” Clinical Chemistry and Laboratory Medicine, vol. 37, pp. 209–213, 1999. View at Publisher · View at Google Scholar · View at Scopus